Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia

Sci Rep. 2020 May 20;10(1):8328. doi: 10.1038/s41598-020-65234-3.

Abstract

Given the prevalence of poor adherence to therapy and the biases of self-reporting across healthcare, we hypothesized that an engaging, personalized therapy may improve adherence and treatment outcomes in the home. We tested this hypothesis in the initial indication of amblyopia, a neurodevelopmental disorder for which available treatments are limited by low adherence. We designed a novel digital therapeutic that modifies patient-selected cinematic content in real-time into therapeutic visual input, while objectively monitoring adherence. The therapeutic design integrated a custom-designed headset that delivers precise visual input to each eye, computational algorithms that apply real-time therapeutic modifications to source content, a cloud-based content management system that enables treatment in the home, and a broad library of licensed content. In a proof-of-concept human study on the therapeutic, we found that amblyopic eye vision improved significantly after 12 weeks of treatment, with higher adherence than that of available treatments. These initial results support the utility of personalized therapy in amblyopia and may have broader relevance for improving treatment outcomes in additional indications.

Publication types

  • Clinical Trial

MeSH terms

  • Algorithms
  • Amblyopia / therapy*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Patient Compliance
  • Patient Satisfaction
  • Treatment Outcome
  • Visual Acuity
  • Wearable Electronic Devices*